• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, August 1, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

How Metformin Effectively Lowers Blood Sugar Levels

Bioengineer by Bioengineer
July 31, 2025
in Health
Reading Time: 4 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

blank

For more than six decades, metformin has stood as the frontline therapy for managing type 2 diabetes, its longstanding clinical use grounded in efficacy and safety. Yet, despite its widespread prescription, the intricate biological mechanisms underlying metformin’s glucose-lowering effects have remained elusive. A groundbreaking study led by researchers at Baylor College of Medicine, in collaboration with international scientists, now unveils a novel dimension of metformin’s action: a pivotal brain pathway that modulates its antidiabetic effects. This discovery challenges the conventional liver- and gut-centric perspectives, opening transformative possibilities for diabetes treatment.

Historically, metformin’s primary glucose-lowering role has been attributed to its suppression of hepatic gluconeogenesis—the liver’s production of glucose—thereby reducing blood sugar levels. Additionally, recent studies highlighted the contribution of the gut, with metformin altering intestinal glucose absorption and gut microbiota composition. However, Dr. Makoto Fukuda and colleagues hypothesized that the central nervous system, particularly the brain, might also serve as an essential mediator in metformin’s systemic regulation of glucose metabolism, given the brain’s central role in energy homeostasis.

Focusing on the ventromedial hypothalamus (VMH), a critical brain region involved in systemic energy regulation, the research zeroed in on a small but influential protein, Rap1. This protein acts as a molecular switch within VMH neurons, potentially influencing how the brain senses and regulates glucose balance. The team’s experiments revealed that metformin’s glucose-lowering prowess at clinically relevant, low doses hinges on its ability to inhibit Rap1 activity in the VMH.

.adsslot_WcY6SanuPx{width:728px !important;height:90px !important;}
@media(max-width:1199px){ .adsslot_WcY6SanuPx{width:468px !important;height:60px !important;}
}
@media(max-width:767px){ .adsslot_WcY6SanuPx{width:320px !important;height:50px !important;}
}

ADVERTISEMENT

To unravel this mechanism, genetically modified mice lacking Rap1 selectively in the VMH were fed a high-fat diet to mirror human type 2 diabetes pathology. Remarkably, when these mice received low-dose metformin, the expected reduction in blood glucose was conspicuously absent, underscoring Rap1’s critical role. Notably, these mice remained responsive to other antidiabetic agents such as insulin and GLP-1 receptor agonists, indicating that the impairment was specific to the metformin-Rap1 axis rather than a broad defect in glucose regulation.

Providing striking support for the brain’s central function, the researchers administered minuscule quantities of metformin directly into the brains of diabetic mice. These intracerebral infusions, measured in doses thousands of times smaller than typical oral administration, elicited a potent hypoglycemic effect. This finding suggests an extraordinary sensitivity of brain circuits to metformin and hints at potential targeted therapies that could harness this pathway with minimal systemic exposure.

Delving into the cellular substrates within the VMH, Dr. Fukuda’s team identified SF1 neurons as pivotal responders to metformin’s action. Electrophysiological recordings from brain slices showed enhanced activity in these neurons following metformin exposure, but importantly, this effect was contingent on the presence of Rap1. In mice genetically devoid of Rap1 specifically in SF1 neurons, metformin failed to activate these cells, reinforcing the protein’s indispensable role in this newly discovered mechanism.

This research revolutionizes the prevailing paradigm of metformin pharmacodynamics. While conventional wisdom emphasized liver and gut tissues as primary sites of action requiring relatively high drug concentrations, the brain’s VMH region appears exquisitely sensitive to metformin at far lower doses. This insight not only broadens understanding of whole-body glucose homeostasis but also unveils new therapeutic targets linked to central nervous system function.

Moreover, the discovery that metformin modulates brain pathways has significant implications beyond glucose control. Metformin has been reported to confer neuroprotective effects, slowing cognitive decline and brain aging in various models. The current study raises the intriguing possibility that Rap1-mediated signaling in the brain may underlie these benefits, warranting intensifying investigations into metformin’s neurobiological impact.

The study’s interdisciplinary team, spanning institutions such as Louisiana State University, Nagoya University, and Meiji University in Japan, combined genetic engineering, pharmacology, and neurophysiology to elucidate these novel mechanisms. Their comprehensive approach, supported by multiple grants from prestigious organizations including the NIH and American Diabetes Association, exemplifies the collaborative spirit driving breakthroughs in metabolic research.

As the global burden of type 2 diabetes continues to climb, advancements that pave the way for more precise interventions are urgently needed. Targeting the brain’s Rap1 pathway could herald a new class of therapies that effectively lower blood glucose with potentially fewer systemic side effects. These findings foster hope for next-generation diabetic treatments tailored to exploit this brain-centric mechanism.

Future studies are set to explore the feasibility of selectively modulating this pathway in humans, including the development of brain-penetrant compounds that mimic metformin’s Rap1 inhibition. Insight into the exact intracellular signaling cascades downstream of Rap1 in SF1 neurons will be pivotal, as will understanding interactions with other metabolic regulators.

In summary, this pioneering research uncovers a crucial role of brain Rap1 in enabling metformin’s antidiabetic effects at low doses, fundamentally reshaping our comprehension of this venerable drug’s mode of action. By integrating neuroscience and metabolic medicine, the study charts a promising course toward innovative diabetes therapies, illuminating the brain’s previously underappreciated contribution to systemic glucose regulation.

Subject of Research: Animals
Article Title: Low-dose metformin requires brain Rap1 for its antidiabetic action
News Publication Date: 30-Jul-2025
Web References: Science Advances article
References: Makoto Fukuda et al., Science Advances, DOI: 10.1126/sciadv.adu3700
Keywords: Diabetes, Metformin, Brain, Rap1, Ventromedial hypothalamus, Glucose metabolism, SF1 neurons, Antidiabetic therapy, Neurobiology, Type 2 diabetes

Tags: antidiabetic drug mechanismsBaylor College of Medicine researchblood sugar regulation mechanismscentral nervous system glucose metabolismgut microbiota and diabetes treatmenthepatic gluconeogenesis suppressionmetformin clinical efficacy and safetymetformin diabetes managementRap1 protein role in diabetestransformative diabetes therapiestype 2 diabetes frontline therapyventromedial hypothalamus function

Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Hearing Loss Reduces Employment Opportunities and Earnings Potential for Young Americans

August 1, 2025
blank

Host-Pathogen Fumarate Control Fuels Staph Pneumonia

August 1, 2025

Decelerated Protein Translation Accelerates Brain Aging in Killifish

August 1, 2025

Neuropsychiatric Risks Linked to COVID-19 Revealed

August 1, 2025

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    60 shares
    Share 24 Tweet 15
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12
  • Study Reveals Beta-HPV Directly Causes Skin Cancer in Immunocompromised Individuals

    37 shares
    Share 15 Tweet 9
  • Engineered Cellular Communication Enhances CAR-T Therapy Effectiveness Against Glioblastoma

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Revolutionary Breakthrough: Achieving Exceptional Performance at Significantly Reduced Temperatures!

Hearing Loss Reduces Employment Opportunities and Earnings Potential for Young Americans

Host-Pathogen Fumarate Control Fuels Staph Pneumonia

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.